Department of Ultrasound, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of China.
Department of Head Neck and Thyroid, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, People's Republic of China.
BMC Cancer. 2020 Oct 27;20(1):1034. doi: 10.1186/s12885-020-07534-5.
The feasibility of submandibular gland (SMG) preservation in oral squamous cell carcinoma (SCC) has occasionally been analyzed, but the differences in survival associated with the presence or absence of SMG preservation remain unknown. We aimed to prospectively evaluate the oncologic results of SMG preservation in cT1-2 N0 buccal SCC.
This was a prospective, non-randomized cohort study. Patients with surgically treated cT1-2 N0 buccal SCC were prospectively enrolled and divided into two groups based on the management of the SMG. Level 1b lymph nodes were categorized into six groups based on the positional relationship between the lymph node and the SMG. The main study endpoints were locoregional control (LRC) and disease-specific survival (DSS).
A total of 31 of the 137 included patients underwent SMG-sparing neck dissection. Patients with SMG preservation were likely to be young persons. Superior metastasis occurred in 11 patients with a prevalence of 8.0%, followed by an anterior metastasis rate of 5.1%, and no metastases developed deeply or within the SMG. The 5-year LRC rates in the SMG-sparing and SMG-excision groups were 74 and 75%, respectively, and the difference was not significant (p = 0.970). The 5-year DSS rates in the SMG-sparing and SMG-excision groups were 74 and 69%, respectively, and the difference was not significant (p = 0.709).
SMG involvement was rare, and the superior group carried the highest risk for lymph node metastasis. SMG-sparing neck dissection is selectively suggested in cT1-2 N0 buccal SCC patients, and could avoid postoperative asymmetric appearance and dry mouth.
下颌下腺(SMG)保留在口腔鳞状细胞癌(SCC)中的可行性偶尔会被分析,但与 SMG 保留与否相关的生存差异尚不清楚。我们旨在前瞻性评估 cT1-2N0 颊 SCC 中 SMG 保留的肿瘤学结果。
这是一项前瞻性、非随机队列研究。对接受手术治疗的 cT1-2N0 颊 SCC 患者进行前瞻性登记,并根据 SMG 的处理方式将其分为两组。1b 级淋巴结根据淋巴结与 SMG 的位置关系分为六组。主要研究终点为局部区域控制(LRC)和疾病特异性生存(DSS)。
在纳入的 137 例患者中,共有 31 例接受了 SMG 保留的颈部清扫术。保留 SMG 的患者更有可能是年轻人。上极转移发生在 11 例患者中,占 8.0%,其次是前极转移率为 5.1%,没有转移发生在深部或 SMG 内。SMG 保留组和 SMG 切除组的 5 年 LRC 率分别为 74%和 75%,差异无统计学意义(p=0.970)。SMG 保留组和 SMG 切除组的 5 年 DSS 率分别为 74%和 69%,差异无统计学意义(p=0.709)。
SMG 受累罕见,上极组淋巴结转移风险最高。SMG 保留的颈部清扫术选择性地适用于 cT1-2N0 颊 SCC 患者,可避免术后不对称外观和口干。